Navigation Links
Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
Date:7/29/2010

tatements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the anticipated action date for the FDA to complete its review of the Contrave NDA, the potential for, and timing of, approval for Contrave and the Company's belief that this product candidate may be an important therapeutic option in the treatment of obesity. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the uncertainty of the FDA approval process and other regulatory requirements; the therapeutic and commercial value of Contrave; reliance on third parties to assist with the development of Contrave; the potential for adverse safety findings relating to Contrave; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on May 10, 2010 and is available from
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015 Biopharmaceutical Industry Leads ... industry comes out on top as the country,s manufacturing ... new report  from ndp│analytics. According to the  analysis , ... investment over the last decade, accounting for 27 percent ... A Short Video on Medicare Part D ...
(Date:3/27/2015)... , March 27, 2015 Zimmer Holdings, Inc. (NYSE and ... NexGen ® Complete Knee System. ... the 20 th year since Zimmer first introduced the NexGen ... market. To date, more than five million implantations of the NexGen ... history of the NexGen knee demonstrates the importance of design ...
(Date:3/27/2015)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... announced registered offering of common shares in ... the Offering, the Company issued 7,286,432 common shares at ... proceeds of approximately $1.45 billion. On March 18, 2015, ... Commission a final prospectus supplement to its effective shelf ...
Breaking Medicine Technology:Week in Review: The Latest from PhRMA 2Zimmer Celebrates Key Milestones For NexGen Complete Knee System 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3
... Inc. (OTCBB: PLCSF), a company focused on innovative medical ... new product, RenalGuard®, at EuroPCR, the annual meeting of ... than 11,000 clinicians and medical professionals from around the ... take place in Paris, France from May 17-20, 2011. ...
... May 12, 2011 CVS Caremark was selected as ... for Best Practices in Health Care Consumer Empowerment and ... the finalists during URAC,s 12th Annual Quality Summit, October ... CVS Caremark,s Pharmacy Advisor program was selected ...
Cached Medicine Technology:PLC to Demonstrate RenalGuard® at EuroPCR 2011 2PLC to Demonstrate RenalGuard® at EuroPCR 2011 3CVS Caremark Named as Finalist for 2011 URAC Award for Best Practices in Health Care Consumer Empowerment and Protection 2CVS Caremark Named as Finalist for 2011 URAC Award for Best Practices in Health Care Consumer Empowerment and Protection 3
(Date:3/28/2015)... March 28, 2015 "Necrorun" was featured ... takes a look at the latest and coolest applications ... Troohey, the host of NewsWatch and technology expert, conducted ... is an entertaining endless runner game with knights, nature, ... was released in 2009, according to Eurogamer. The popularity ...
(Date:3/28/2015)... With more than 4,500 scientists, ... osteoporosis, osteoarthritis and musculoskeletal diseases gathered here for ... the first time in the 17-year history of ... hot-button topic is an emerging non-pharmaceutical protocol for ... principles of Wolff’s law, osteogenic loading at multiples ...
(Date:3/28/2015)... The California-based leading wig brand UniWigs ... shopping on UniWigs during the Easter Holidays from today ... promotion on April Fools’ Day. , As the winter ... the corner. Easter Festival, with religious origins to countries ... holiday after Christmas. The best wig provider, UniWigs, would ...
(Date:3/28/2015)... March 28, 2015 India Network ... is made available to all visitors who purchase the ... All members are encouraged to purchase the insurance program ... lack of proper coverage for pre-existing medical conditions. Parents ... or two medical conditions with serious consequences to their ...
(Date:3/28/2015)... Chicago, IL (PRWEB) March 28, 2015 Centurion ... medical equipment auction on Thursday, April 2 at their Las ... Las Vegas, NV 89081. The sale, which consists of equipment ... will begin promptly at 9 a.m. PDT. , Buyers ... radiology and surgery equipment. “We are a one-stop-shop,” said Erik ...
Breaking Medicine News(10 mins):Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Medical Equipment Auction to Take Place in North Las Vegas 2
... PITTSBURGH, June 17 Mylan Inc. (Nasdaq: MYL ... received approval from the U.S. Food and Drug Administration (FDA) ... Capsules USP, 22.5 mg. This strength is in addition to ... the product. , , Temazepam Capsules are the generic ...
... Dad,s Personal Wellness ,Toolbox, Gets a Makeover with the Omron HEM-780 Blood ... Day, all eyes are on dad. From where to treat him ... role in the family and showing him how much we care. ... So this Father,s Day, rather than giving the usual cordless drill ...
... bankruptcy, and divorce skyrocket with the global recession, the people ... burden of these concerns can be agonizing, affecting both mental ... How to Defeat Stress Without Going Through the Embarrassment of ... of stress life can throw your way. Dr. Theu explains ...
... Footprint , , - Transaction Expected to be Accretive to ... - Enhances Watson,s Long Term Growth Profile , , MORRISTOWN, ... ) today announced that it has entered into a definitive agreement ... and stock. The combination of Watson and Arrow will result in ...
... , , , Oncology Test Further ... Calif., June 17 Cepheid (Nasdaq: CPHD ) today ... be marketed as a CE IVD product under the European Directive ... the test now detects the BCR-ABL chromosomal translocation in about 2 ...
... Group has revealed that despite the drooping economy Scots men ... in for moob removal surgery and finally getting their insecurities ... Transform Cosmetic Surgery Group has revealed that despite the ... this summer by booking in for moob removal surgery and ...
Cached Medicine News:Health News:This Father's Day Give Dad a Gift Straight for the Heart 2Health News:This Father's Day Give Dad a Gift Straight for the Heart 3Health News:'7 Proven Steps: How to Defeat Stress Without Going Through the Embarrassment of Counseling': Proven Ways to Defeat Stress 2Health News:'7 Proven Steps: How to Defeat Stress Without Going Through the Embarrassment of Counseling': Proven Ways to Defeat Stress 3Health News:Watson to Acquire Arrow Group 2Health News:Watson to Acquire Arrow Group 3Health News:Watson to Acquire Arrow Group 4Health News:Watson to Acquire Arrow Group 5Health News:Watson to Acquire Arrow Group 6Health News:Watson to Acquire Arrow Group 7Health News:Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML) 2Health News:Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML) 3Health News:Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML) 4Health News:Scots Men Get the Issue of Moobs Off Their Chests in Time for Summer - Male Surgery in Scotland Sees 80 Per Cent Growth 2Health News:Scots Men Get the Issue of Moobs Off Their Chests in Time for Summer - Male Surgery in Scotland Sees 80 Per Cent Growth 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: